MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; Iranian Center for Neurological Research, Neuroscience Institute, Tehran University of Medical Science, Tehran, Iran.
MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; Iranian Center for Neurological Research, Neuroscience Institute, Tehran University of Medical Science, Tehran, Iran.
Mult Scler Relat Disord. 2018 Apr;21:69-70. doi: 10.1016/j.msard.2018.02.015. Epub 2018 Feb 14.
Fingolimod, taken orally once per day, is approved for the treatment of relapsing-remitting multiple sclerosis (MS). It should be stopped at least two months before conception as it is not considered safe during pregnancy or when breast feeding. In vitro and animal studies have found a possibly increased risk of congenital abnormalities following exposure to Fingolimod. Here, we report a 34-year-old female, with a 10-year history of MS who had unexpected pregnancy with exposure to generic Fingolimod during the first 7 weeks. The infant was born with dextrocardia, but without any further structural cardiac or other abnormalities.
芬戈莫德，每日口服一次，获批用于治疗复发缓解型多发性硬化症（MS）。在受孕前至少应停药两个月，因为该药在妊娠或哺乳期间不安全。体外和动物研究发现，接触芬戈莫德后，先天畸形的风险可能会增加。在此，我们报告了一位 34 岁女性，患有 MS 病史 10 年，在怀孕第 7 周前接触了芬戈莫德仿制药，结果意外怀孕。婴儿出生时患有右位心，但没有任何进一步的结构性心脏或其他异常。
